SK Bioscience

The South Korea government plans to improve the transparency and objectivity of standards for pharma firms to officially qualify as “innovative” and eligible for special policy treatment, amid foreign

Mergers and acquisitions usually happen in major global biopharma markets as a way to gain new technologies, R&D or commercial portfolios, expand a business or to beef up supply networks. But in S

The fourth quarter marked a continuation of weak earnings for many major South Korean pharma firms, hurt by factors including the continued impact of a long-running doctors’ protest against medical r

Major South Korean pharma firms have reported mixed earnings for the third quarter ended 30 September, with Yuhan logging strong earnings after the US approval of its novel lung cancer drug and Hanmi